Autolus Therapeutics Ltd – (NASDAQ:AUTL) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus price objective of $37.50 for the company, according to Zacks. Zacks has also assigned Autolus Therapeutics an industry rank of 97 out of 255 based on the ratings given to its competitors.

AUTL has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued a “buy” rating and a $37.00 price target for the company. Wells Fargo & Co initiated coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued an “outperform” rating and a $38.00 price target for the company. William Blair initiated coverage on Autolus Therapeutics in a report on Tuesday, July 17th. They issued an “outperform” rating for the company. Finally, Goldman Sachs Group began coverage on Autolus Therapeutics in a report on Thursday, July 26th. They issued a “neutral” rating for the company.

NASDAQ:AUTL traded down $0.79 during trading hours on Tuesday, reaching $29.05. The company had a trading volume of 8,200 shares, compared to its average volume of 90,593. Autolus Therapeutics has a 1-year low of $19.17 and a 1-year high of $33.50.

Several institutional investors have recently bought and sold shares of the company. Granahan Investment Management Inc. MA purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at approximately $2,610,000. Millennium Management LLC purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at approximately $3,910,000. Partner Fund Management L.P. purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at approximately $5,301,000. Aquilo Capital Management LLC purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at approximately $4,018,000. Finally, Baker BROS. Advisors LP purchased a new stake in shares of Autolus Therapeutics in the second quarter valued at approximately $6,304,000. Institutional investors and hedge funds own 21.06% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Featured Article: Diversification Important in Investing

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.